Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Income (2018 - 2025)

Cyclerion Therapeutics has reported Operating Income over the past 7 years, most recently at -$1.0 million for Q3 2025.

  • For Q3 2025, Operating Income rose 10.82% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$3.6 million, up 38.68%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
  • Operating Income for Q3 2025 was -$1.0 million at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Over five years, Operating Income peaked at $502000.0 in Q4 2024 and troughed at -$16.2 million in Q2 2021.
  • A 5-year average of -$5.9 million and a median of -$3.3 million in 2023 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: plummeted 33.13% in 2023 and later soared 127.97% in 2024.
  • Year by year, Operating Income stood at -$14.3 million in 2021, then soared by 68.93% to -$4.5 million in 2022, then soared by 59.71% to -$1.8 million in 2023, then soared by 127.97% to $502000.0 in 2024, then crashed by 300.4% to -$1.0 million in 2025.
  • Business Quant data shows Operating Income for CYCN at -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.